Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 25, 2022

View Archived Issues

YAP1/TAZ signaling plays a role in colorectal cancer

CAR plus a CD38-directed chimeric costimulatory receptor enhances tumor killing

Suzhou Vintagence Pharma discloses new GTPase KRAS mutant inhibitors

Chinese researchers patent new antibacterial compounds

Wuhan LL Science and Technology Development divulges TRPC5 antagonists

Medshine Discovery synthesizes new ER-alpha degradation inducers

Shanghai Newsky Biotechnology identifies PLA2G7 inhibitors

CBD inhibits SARS-CoV-2 replication during early stages of infection in mice

Qualigen to develop G4-selective transcription inhibitor from UCL for cancer

PL-8177 shows promise in preclinical models of induced colitis

KIN-3248 shows efficacy against tumors with clinically relevant FGFR mutations

ImmVira leverages viral vectors to enable CAR-T therapy for solid tumors

AB1 protein targets TP53-mutated gastrointestinal tumors

Anixa and MolGenie report in vitro data on SARS-CoV-2 protease inhibitor

Molecular mimicry triggers multiple sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...